Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 11Gastrointestinal 3Gynecologic 2Thoracic 1Sarcoma 1Other solid neoplasm 1Other hematologic neoplasm 1Head & Neck 1Genitourinary 1Dermatologic 1

Conditions

Leukemia, Myeloid, Acute 4Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Recurrence 1Neoplasm, Residual 1Myelodysplastic Syndromes 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Carcinoma 1

Interventions

Paclitaxel 2tislelizumab 1stenoparib 1sargramostim 1pembrolizumab 1margetuximab 1bintrafusp alfa protein, human 1Temozolomide 1Standard of Care 1Specimen Handling 1Practice Guidelines as Topic 1Paracentesis 1Palliative Care 1N-(2,3-dihydroxypropyl)-1-((2-fluoro-4-iodophenyl)amino)isonicotinamide 1Monatide (IMS 3015) 1Magnetic Resonance Spectroscopy 1Granulocyte-Macrophage Colony-Stimulating Factor 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × tislelizumab × Other hematologic neoplasm × Clear all
NCT05768932 2026-03-27

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

SillaJen, Inc.

Phase 1 Recruiting
260 enrolled
BreastGastrointestinalOther hematologic neoplasm

Carcinoma, Stomach Neoplasms, Leukemia, Myeloid, Acute, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡